The ability of Adenovirus (Ad) and DNA electroporation (DNA-EP) based vaccine to induce immune responses against dog Telomerase (dTERT) and its impact on survival have been evaluated in 20 dogs affected by malignant lymphoma (ML). The vaccine was combined with chemotherapy regimen (cyclophosphamide, vincristine and prednisone). The immune response was documented by immunological assays. Overall survival and time-to- first relapse were evaluated. dTERT-specific immune response was induced in almost all animals and remained detectable and long-lasting with the absence of apparent autoimmunity or other side-effects. Most interestingly, the survival time of vaccine/Chemo treated dogs was significantly increased over controls of Chemo-treated animals (>82 vs 37 weeks, respectively, p=0.000141). Currently, 4 vaccinated dogs are alive and in complete remission. This data support further evaluation of this approach in Phase II/III veterinary trials.
Un vaccino contro la telomerasi aumenta la sopravvivenza nei cani affetti da linfoma
GAVAZZA, ALESSANDRA;LUBAS, GEORGE;
2011-01-01
Abstract
The ability of Adenovirus (Ad) and DNA electroporation (DNA-EP) based vaccine to induce immune responses against dog Telomerase (dTERT) and its impact on survival have been evaluated in 20 dogs affected by malignant lymphoma (ML). The vaccine was combined with chemotherapy regimen (cyclophosphamide, vincristine and prednisone). The immune response was documented by immunological assays. Overall survival and time-to- first relapse were evaluated. dTERT-specific immune response was induced in almost all animals and remained detectable and long-lasting with the absence of apparent autoimmunity or other side-effects. Most interestingly, the survival time of vaccine/Chemo treated dogs was significantly increased over controls of Chemo-treated animals (>82 vs 37 weeks, respectively, p=0.000141). Currently, 4 vaccinated dogs are alive and in complete remission. This data support further evaluation of this approach in Phase II/III veterinary trials.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
